{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:10:58Z","timestamp":1790874658684,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims\/hypothesis<\/jats:title>\n                    <jats:p>Higher plasma concentrations of tumour necrosis factor receptor (TNFR)-1, TNFR-2 and kidney injury molecule-1 (KIM-1) have been found to be associated with higher risk of kidney failure in individuals with type 2 diabetes in previous studies. Whether drugs can reduce these biomarkers is not well established. We measured these biomarkers in samples of the CANVAS study and examined the effect of the sodium\u2013glucose cotransporter 2 inhibitor canagliflozin on these biomarkers and assessed whether the early change in these biomarkers predict cardiovascular and kidney outcomes in individuals with type 2 diabetes in the CANagliflozin cardioVascular Assessment Study (CANVAS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Biomarkers were measured with immunoassays (proprietary multiplex assay performed by RenalytixAI, New York, NY, USA) at baseline and years 1, 3 and 6. Mixed-effects models for repeated measures assessed the effect of canagliflozin vs placebo on the biomarkers. Associations of baseline levels and the early change (baseline to year 1) for each biomarker with the kidney outcome were assessed using multivariable-adjusted Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 3523\/4330 (81.4%) of the CANVAS participants had available samples at baseline. Each doubling in baseline TNFR-1, TNFR-2 and KIM-1 was associated with a higher risk of kidney outcomes, with corresponding HRs of 3.7 (95% CI 2.3, 6.1;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), 2.7 (95% CI 2.0, 3.6;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) and 1.5 (95% CI 1.2, 1.8;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), respectively. Canagliflozin reduced the level of the plasma biomarkers with differences in TNFR-1, TNFR-2 and KIM-1 between canagliflozin and placebo during follow-up of 2.8% (95% CI 3.4%, 1.3%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), 1.9% (95% CI 3.5%, 0.2%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03) and 26.7% (95% CI 30.7%, 22.7%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), respectively. Within the canagliflozin treatment group, each 10% reduction in TNFR-1 and TNFR-2 at year 1 was associated with a lower risk of the kidney outcome (HR 0.8 [95% CI 0.7, 1.0;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02] and 0.9 [95% CI 0.9, 1.0;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01] respectively), independent of other patient characteristics. The baseline and 1\u00a0year change in biomarkers did not associate with cardiovascular or heart failure outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\/interpretation<\/jats:title>\n                    <jats:p>Canagliflozin decreased KIM-1 and modestly reduced TNFR-1 and TNFR-2 compared with placebo in individuals with type 2 diabetes in CANVAS. Early decreases in TNFR-1 and TNFR-2 during canagliflozin treatment were independently associated with a lower risk of kidney disease progression, suggesting that TNFR-1 and TNFR-2 have the potential to be pharmacodynamic markers of response to canagliflozin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00125-021-05512-5","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T10:04:15Z","timestamp":1629453855000},"page":"2147-2158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial"],"prefix":"10.1007","volume":"64","author":[{"given":"Taha","family":"Sen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9276-8380","authenticated-orcid":false,"given":"Brendon L.","family":"Neuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0490-7465","authenticated-orcid":false,"given":"Bruce","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Arnott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9051-7385","authenticated-orcid":false,"given":"Chirag R.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0928-9168","authenticated-orcid":false,"given":"Steven G.","family":"Coca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yshai","family":"Yavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"issue":"suppl 1","key":"5512_CR1","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2337\/dc14-S014","volume":"37","author":"American Diabetes Association","year":"2014","unstructured":"American Diabetes Association (2014) Standards of medical care in diabetes--2014. Diabetes Care 37(suppl 1):S14\u2013S80. https:\/\/doi.org\/10.2337\/dc14-S014","journal-title":"Diabetes Care"},{"issue":"8","key":"5512_CR2","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1681\/ASN.2014070688","volume":"26","author":"HJ Heerspink","year":"2015","unstructured":"Heerspink HJ, Kropelin TF, Hoekman J, de Zeeuw D, Reducing Albuminuria as Surrogate Endpoint (REASSURE) Consortium (2015) Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol 26(8):2055\u20132064. https:\/\/doi.org\/10.1681\/ASN.2014070688","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"5512_CR3","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","volume":"60","author":"National Kidney Foundation","year":"2012","unstructured":"National Kidney Foundation (2012) KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 60(5):850\u2013886. https:\/\/doi.org\/10.1053\/j.ajkd.2012.07.005","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"5512_CR4","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR (2017) Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 12(12):2032\u20132045. https:\/\/doi.org\/10.2215\/CJN.11491116","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"5512_CR5","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1681\/ASN.2016101101","volume":"28","author":"SG Coca","year":"2017","unstructured":"Coca SG, Nadkarni GN, Huang Y et al (2017) Plasma biomarkers and kidney function decline in early and established diabetic kidney disease. J Am Soc Nephrol 28(9):2786\u20132793. https:\/\/doi.org\/10.1681\/ASN.2016101101","journal-title":"J Am Soc Nephrol"},{"key":"5512_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1146\/annurev.iy.10.040192.002211","volume":"10","author":"P Vassalli","year":"1992","unstructured":"Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411\u2013452. https:\/\/doi.org\/10.1146\/annurev.iy.10.040192.002211","journal-title":"Annu Rev Immunol"},{"issue":"16","key":"5512_CR7","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1042\/CS20171459","volume":"132","author":"JC Jha","year":"2018","unstructured":"Jha JC, Ho F, Dan C, Jandeleit-Dahm K (2018) A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes. Clin Sci (Lond) 132(16):1811\u20131836. https:\/\/doi.org\/10.1042\/CS20171459","journal-title":"Clin Sci (Lond)"},{"issue":"5","key":"5512_CR8","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41591-019-0415-5","volume":"25","author":"MA Niewczas","year":"2019","unstructured":"Niewczas MA, Pavkov ME, Skupien J et al (2019) A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat Med 25(5):805\u2013813. https:\/\/doi.org\/10.1038\/s41591-019-0415-5","journal-title":"Nat Med"},{"issue":"1","key":"5512_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1046\/j.1523-1755.2002.00433.x","volume":"62","author":"WK Han","year":"2002","unstructured":"Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV (2002) Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 62(1):237\u2013244. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00433.x","journal-title":"Kidney Int"},{"issue":"3","key":"5512_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1681\/ASN.2011060627","volume":"23","author":"MA Niewczas","year":"2012","unstructured":"Niewczas MA, Gohda T, Skupien J et al (2012) Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 23(3):507\u2013515. https:\/\/doi.org\/10.1681\/ASN.2011060627","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"5512_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/ki.2014.285","volume":"87","author":"RS Al-Lamki","year":"2015","unstructured":"Al-Lamki RS, Mayadas TN (2015) TNF receptors: signaling pathways and contribution to renal dysfunction. Kidney Int 87(2):281\u2013296. https:\/\/doi.org\/10.1038\/ki.2014.285","journal-title":"Kidney Int"},{"issue":"24","key":"5512_CR12","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, CREDENCE Trial Investigators et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"issue":"3","key":"5512_CR13","doi-asserted-by":"publisher","first-page":"e014908","DOI":"10.1161\/JAHA.119.014908","volume":"9","author":"C Arnott","year":"2020","unstructured":"Arnott C, Li Q, Kang A et al (2020) Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc 9(3):e014908. https:\/\/doi.org\/10.1161\/JAHA.119.014908","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"5512_CR14","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, CANVAS Program Collaborative Group et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"issue":"11","key":"5512_CR15","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL et al (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7(11):845\u2013854. https:\/\/doi.org\/10.1016\/S2213-8587(19)30256-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"5512_CR16","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/dom.13301","volume":"20","author":"CCJ Dekkers","year":"2018","unstructured":"Dekkers CCJ, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJL (2018) Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab 20(8):1988\u20131993. https:\/\/doi.org\/10.1111\/dom.13301","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"5512_CR17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s13300-017-0274-3","volume":"8","author":"M Matsumura","year":"2017","unstructured":"Matsumura M, Nakatani Y, Tanka S et al (2017) Efficacy of additional canagliflozin administration to type 2 diabetes patients receiving insulin therapy: examination of diurnal glycemic patterns using continuous glucose monitoring (CGM). Diabetes Ther 8(4):821\u2013827. https:\/\/doi.org\/10.1007\/s13300-017-0274-3","journal-title":"Diabetes Ther"},{"issue":"7","key":"5512_CR18","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","volume":"62","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Perco P, Mulder S et al (2019) Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia 62(7):1154\u20131166. https:\/\/doi.org\/10.1007\/s00125-019-4859-4","journal-title":"Diabetologia"},{"issue":"2","key":"5512_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ahj.2013.05.007","volume":"166","author":"B Neal","year":"2013","unstructured":"Neal B, Perkovic V, de Zeeuw D et al (2013) Rationale, design, and baseline characteristics of the Canagliflozin cardiovascular assessment study (CANVAS)--a randomized placebo-controlled trial. Am Heart J 166(2):217\u2013223e11. https:\/\/doi.org\/10.1016\/j.ahj.2013.05.007","journal-title":"Am Heart J"},{"issue":"3","key":"5512_CR20","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.kint.2020.04.051","volume":"98","author":"J Li","year":"2020","unstructured":"Li J, Neal B, Perkovic V et al (2020) Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney Int 98(3):769\u2013777. https:\/\/doi.org\/10.1016\/j.kint.2020.04.051","journal-title":"Kidney Int"},{"issue":"4","key":"5512_CR21","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/ki.2014.330","volume":"87","author":"ME Pavkov","year":"2015","unstructured":"Pavkov ME, Nelson RG, Knowler WC, Cheng Y, Krolewski AS, Niewczas MA (2015) Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney Int 87(4):812\u2013819. https:\/\/doi.org\/10.1038\/ki.2014.330","journal-title":"Kidney Int"},{"issue":"1","key":"5512_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12020-019-02153-y","volume":"68","author":"D Cheng","year":"2020","unstructured":"Cheng D, Fei Y, Saulnier PJ, Wang N (2020) Circulating TNF receptors and risk of renal disease progression, cardiovascular disease events and mortality in patients with diabetes: a systematic review and meta-analysis. Endocrine 68(1):32\u201343. https:\/\/doi.org\/10.1007\/s12020-019-02153-y","journal-title":"Endocrine"},{"issue":"6","key":"5512_CR23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/ejhf.426","volume":"18","author":"JE Emmens","year":"2016","unstructured":"Emmens JE, Ter Maaten JM, Matsue Y et al (2016) Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome. Eur J Heart Fail 18(6):641\u2013649. https:\/\/doi.org\/10.1002\/ejhf.426","journal-title":"Eur J Heart Fail"},{"key":"5512_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.atherosclerosis.2017.05.021","volume":"263","author":"M Park","year":"2017","unstructured":"Park M, Maristany D, Huang D, Shlipak MG, Whooley M (2017) Associations of tumor necrosis factor alpha receptor type 1 with kidney function decline, cardiovascular events, and mortality risk in persons with coronary artery disease: data from the heart and soul study. Atherosclerosis 263:68\u201373. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.05.021","journal-title":"Atherosclerosis"},{"key":"5512_CR25","doi-asserted-by":"publisher","unstructured":"Al-Lamki RS, Wang J, Skepper JN, Thiru S, Pober JS, Bradley JR (2001) Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Lab Invest 81(11):1503\u20131515. https:\/\/doi.org\/10.1038\/labinvest.3780364","DOI":"10.1038\/labinvest.3780364"},{"issue":"11","key":"5512_CR26","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","volume":"33","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Brosius FC 3rd, Adler SG et al (2018) JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase 2 randomized controlled clinical trial. Nephrol Dial Transplant 33(11):1950\u20131959. https:\/\/doi.org\/10.1093\/ndt\/gfx377","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"5512_CR27","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1093\/ndt\/gfx377","volume":"21","author":"CCJ Dekkers","year":"2019","unstructured":"Dekkers CCJ, Sjostrom CD, Greasley PJ, Cain V, Boulton DW, Heerspink HJL (2019) Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes Obes Metab 21(12):2667\u20132673. https:\/\/doi.org\/10.1093\/ndt\/gfx377","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-021-05512-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-021-05512-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-021-05512-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T03:05:37Z","timestamp":1630983937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-021-05512-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5512"],"URL":"https:\/\/doi.org\/10.1007\/s00125-021-05512-5","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"assertion":[{"value":"28 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}